Investigational Site Number : 0320005
Buenos Aires, Argentina
8 recruiting
Showing 1–14 of 14 trials
Recruiting
Phase 2
A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)
Juvenile Idiopathic Arthritis
Sanofi51 enrolled31 locationsNCT02991469
Recruiting
Phase 3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
Sanofi210 enrolled121 locationsNCT06834347
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Colitis Ulcerative
Sanofi204 enrolled115 locationsNCT06867094
Recruiting
Phase 3
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
Chronic Rhinosinusitis With Nasal Polyps
Sanofi210 enrolled113 locationsNCT06834360
Recruiting
Phase 3
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
Type 1 Diabetes Mellitus
Sanofi723 enrolled141 locationsNCT07088068
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Crohn's Disease
Sanofi260 enrolled138 locationsNCT06637631
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled188 locationsNCT07190222
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled166 locationsNCT07190209
Recruiting
Phase 2
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Asthma
Sanofi1,147 enrolled236 locationsNCT06676319
Recruiting
Phase 3
Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
Pruritus
Sanofi284 enrolled91 locationsNCT05263206
Recruiting
Phase 2
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma.
Asthma
Sanofi900 enrolled118 locationsNCT06609239
Recruiting
Phase 2
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Dermatitis Atopic
Sanofi901 enrolled175 locationsNCT05769777
Recruiting
Phase 3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Sanofi124 enrolled66 locationsNCT07190196
Recruiting
Phase 3
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
AsthmaWheezing
Sanofi90 enrolled74 locationsNCT06191315